Recordati stock edges lower as bid speculation stays in focus
Published on 09/02/2026 at 19:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Recordati (ISIN IT0003828271) stock traded at 52.15 euros in the FTSE MIB overview on September 2, 2026, slightly below the prior price of 52.35 euros, corresponding to a daily move of about minus 0.4 percent according to a price table from Borsa Italiana.
Stock move and bid backdrop
In the FTSE MIB daily performance table dated September 2, 2026, Recordati Ord is shown with a last value of 52.15 euros and a reference price of 52.35 euros, with the percentage change line indicating a negative move of 0.38 percent, underlining a modest decline for the stock in a generally active Italian blue-chip environment as reported by Borsa Italiana.
The share price behavior comes against the backdrop of ongoing private equity interest in Recordati, highlighted in a recent markets article discussing how a consortium led by CVC Capital Partners has tabled a bid of 12.4 billion dollars to take the Italian drugmaker private, a proposal that continues to frame investor expectations for future ownership structure according to a summary carried by a US financial portal.
Earnings and fundamentals context
For investors, the latest available reported figures for Recordati remain central when judging the bid backdrop and the valuation reflected in the current trading level around 52 euros; while the intraday move on September 2, 2026 is contained, the price level itself sits in the upper mid range of typical large-cap Italian pharmaceutical valuations, implying that the market is already pricing in a premium relative to purely stand-alone fundamentals.
The current quotation around 52.15 euros also serves as a reference point relative to longer-term levels; for example, if the 52-week range were to span from roughly the low 40-euro area to the mid 50-euro area, the present price would be close to the upper end of that corridor, an indication that bid speculation and sector rotation into defensive healthcare names are supporting the share despite the slight negative daily change on September 2, 2026.
Further Recordati stock data and disclosures
More detailed quote information and company disclosures for Recordati can be found via the thematic overview and the group's own investor relations page.
Key products in specialty pharma
The Italian pharmaceutical group focuses on prescription and specialty medicines, including treatments in areas such as cardiovascular and rare diseases, which help underpin a relatively stable revenue profile and attract long-term investors looking for defensive exposure in the healthcare segment.
Recordati stock and investor view
With Recordati stock at 52.15 euros on September 2, 2026 on Borsa Italiana and a small daily decline of 0.38 percent versus the previous price, the share remains an actively traded component of the FTSE MIB index, and the combination of fundamental earnings power, defensive product portfolio and ongoing takeover interest continues to shape how investors assess the risk-reward profile at current levels.
Recordati at a glance
- Company: Recordati S.p.A.
- ISIN: IT0003828271
- Ticker: REC
- Trading venue: Borsa Italiana
- Price (as of September 2, 2026): 52.15 euros
- Sector / Industry: Pharmaceuticals
- Index membership: FTSE MIB
